News
Gene team supports therapies for previously untreatable brain regions
In a promising step for next-generation gene therapy for neurological diseases, Novartis and Voyager Therapeutics have announced a licence option agreement.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
In a promising step for next-generation gene therapy for neurological diseases, Novartis and Voyager Therapeutics have announced a licence option agreement.